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Clinical Perspective
Clopidogrel is metabolized in the Cytochrome P450 (CYP) pathway to its active metabolite and smoking is an inducer of CYP1A2.
Recent in vitro data suggest that smoking influences the platelet inhibitory effect of clopidogrel, yet the relationship between clopidogrel,
smoking and clinical outcomes is incompletely understood. The objectives of this study were two-fold: first, to evaluate the relationship
between smoking status (current, former and never) on all-cause, cardiovascular, and cancer mortality in patients with established
cardiovascular disease, and second, to investigate the safety and efficacy of clopidogrel versus placebo stratified by smoking status.
Among patients with established cardiovascular disease, smoking status is a strong independent risk factor for all cause mortality,
cardiovascular mortality, cancer mortality, cardiovascular events, and bleeding risk. A significant interaction existed between current
smokers and clopidogrel use for the outcomes of all-cause and cardiovascular mortality. Clopidogrel was most effective in reducing all-
cause and cardiovascular mortality, while simultaneously increasing the risk of bleeding in current smokers, a finding not observed in
former or never smokers. The current analysis extends and reinforces the increase in total and cause-specific mortality caused by smoking,
as well as the increase in bleeding in a population with established cardiovascular disease. The data suggest an important relationship
between smoking status and the safety and efficacy of clopidogrel therapy. Further studies are needed to investigate this possibility.
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Abstract
Background—Smoking increases platelet aggregability, and the degree of platelet inhibition by
clopidogrel on ex vivo platelet function tests. Whether smoking status affects the relationship
between clopidogrel and clinical outcomes is unknown.
Methods and Results—We evaluated the relationship between smoking status (current smoker
(CS), former smoker (FS), and never smoker (NS)) and treatment with clopidogrel on the risk of all-
cause, cardiovascular, and cancer mortality among the 12,152 participants from the CHARISMA
trial with established cardiovascular disease. Current smoking was associated with an increase in all-
cause (adjusted hazard ratio [HR] 2.58, [1.85–3.60]), cardiovascular (HR 2.26, [1.48–3.45]), and
cancer mortality (HR 4.16, [2.46–7.03]) compared to NS. The impact of clopidogrel and mortality
differed by smoking status (P for interaction = 0.018 for current smokers). Among CS, clopidogrel
was associated with a reduction in all-cause mortality (HR 0.68, [0.49–0.94]); clopidogrel did not
reduce all cause mortality among FS (HR 0.95, [0.75–1.19]) or NS (HR 1.14, [0.83–1.58]). A similar
pattern was noted for cardiovascular mortality. As expected, no relationship was observed between
clopidogrel and cancer mortality by smoking status. The risk of bleeding seemed to differ according
to smoking status; randomized clopidogrel was associated with a significantly increased hazard of
severe or moderate bleeding (HR 1.62, P=0.04) among CS, but a smaller and nonsignificant increase
among NS (HR 1.31, P=0.15).
Conclusion—Clopidogrel therapy may be more effective, but with a greater bleeding risk in CS
than in patients who are not smokers. Further studies are needed to investigate this possibility.
Keywords
Smoking; Clopidogrel; Mortality; Cardiovascular disease
More than 80 million people have cardiovascular disease in the United States1. Although recent
data suggest improving outcomes in this high-risk population2, the overall mortality rate
remains quite high and cardiovascular disease is the number one killer in the United States1.
Considerable research has been directed at improving outcomes in this population3. Because
of its high associated morbidity and mortality, the influence of smoking in this population
remains a major topic of interest and concern4–6. Cigarette smoking has a number of adverse
effects which influence the cardiovascular system and overall health5. Smoking causes
endothelial dysfunction, dyslipidemia, and increased platelet activation leading to a
prothrombotic state7–9. Smoking increases insulin resistance and diabetes10, 11, and is
associated with increases in emerging biomarkers, including fibrinogen, factor VII,
homocysteine, and C-reactive protein12, 13. Thus, a number of mechanisms may help explain
the heightened risk of cardiovascular disease in smokers.
Many reports have consistently demonstrated a significant adverse relationship between
smoking and mortality14. Risk induced by smoking increases dramatically with the number of
cigarettes smoked daily15. Data from several reports noted a significant relationship between
total and cause specific mortality in male and female smokers16–18. A recent report from the
Nurses Health Study demonstrated that excess vascular mortality may rapidly decrease upon
cessation, but lung disease mortality may take up to 20 years19. The relationship between
smoking status, total mortality, and cause-specific mortality in patients with established
cardiovascular disease in the current era is less well established.
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Recent laboratory data suggest that smoking influences the antiplatelet effect of
clopidogrel20. Cigarette smoking is an inducer of CYP1A221, a hepatic enzyme involved in
the metabolism of clopidogrel22. Clopidogrel has been reported to result in greater inhibition
of platelet aggregation in smokers than non-smokers20, suggesting that the pharmacodynamic
response to clopidogrel may be modified by smoking. In studies that assessed the variability
of platelet response to clopidogrel, smokers were less likely to be hyporesponders than non-
smokers23. Whether smoking affects clinical outcomes in patients receiving clopidogrel
remains uncertain.
The objectives of this study were two-fold: first, to evaluate the relationship between smoking
status (current, former and never) on all-cause, cardiovascular, and cancer mortality in patients
with established cardiovascular disease, and second, to investigate the safety and efficacy of
clopidogrel versus placebo according to smoking status. We hypothesized that, in patients with
established cardiovascular disease, current smokers would be at greatest risk for all-cause
mortality, cardiovascular mortality and cancer mortality. Since smoking appears to augment
the antiplatelet effects of clopidogrel, we postulated that clopidogrel would have a greater
benefit and higher bleeding risk than placebo in current smokers than in former smokers or
those who had never smoked.
Methods
The design, methods, and primary results of the Clopidogrel for High Atherothrombotic Risk
and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial have been
described in detail previously24. To briefly summarize, CHARISMA was a prospective,
multicenter, double-blind, randomized, placebo-controlled trial comparing clopidogrel 75 mg/
day versus placebo long-term in patients at high risk for cardiovascular events. All patients
also received aspirin (75 to 162 mg/day). After a median follow-up of 28 months, clopidogrel
was no more effective than placebo at reducing the rate of myocardial infarction, stroke or
cardiovascular death25.
For this study, we analyzed the impact of smoking status on mortality, cardiovascular events,
and severe or moderate bleeding in subjects with established cardiovascular disease.
Additionally, we evaluated the differential treatment effect (interaction) of clopidogrel versus
placebo according to smoking status. Since smoking status was also used as an entry criterion
for inclusion into the study for patients without established cardiovascular disease, patients
without established cardiovascular disease were excluded from this analysis. We divided the
remaining 12,152 patients with established cardiovascular disease into 3 groups, according to
smoking status: current smokers, former smokers, and patients who never smoked. Current
smokers were defined by a person smoking at least 1 cigarette per day during the month before
enrollment. Former smokers were defined by a person smoking at least 1 cigarette per day at
any time prior to the month before enrollment. Rates of permanently discontinuing clopidogrel
did not differ by smoking status (current smoker – 19.4%, former smoker – 18.9%, never
smoker – 18.2%, Chi-Square p-value = 0.51). The median follow-up time was the same as in
the main study (28 months).
We compared the relationship between current smokers versus never smokers, former smokers
versus never smokers, and current smokers versus former smokers on all-cause mortality,
mortality sub-type, cardiovascular events, and risk of severe or moderate bleeding. In addition,
we compared the relative efficacy of clopidogrel versus placebo on all-cause, cardiovascular,
and cancer mortality according to smoking status. Additionally, we compared the relative
safety of clopidogrel versus placebo on severe or moderate bleeding (determined by the
GUSTO criteria26) according to smoking status. These events were adjudicated by the
Cleveland Clinic Clinical Events Adjudication Committee.
Berger et al. Page 3
Circulation. Author manuscript; available in PMC 2010 December 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Statistical Analysis
All data analyses were performed on the intention-to-treat population. Hypothesis tests were
done using 2-sided tests at the 5% significance level. Baseline characteristics were compared
with chi-square tests for discrete and analysis of variance for continuous variables. The adverse
outcomes were compared using a two-sided log-rank test and were plotted using cumulative
Kaplan-Meier estimates of the event rates. Hazard ratios and their 95% confidence intervals
was estimated using Cox proportional hazards model.
Multivariable Cox proportional hazards models were created to assess the relationship of the
smoking status and the adverse outcomes after adjusting for baseline demographic and clinical
history variables. Indicator variables of current smoker, former smoker versus never smoker
were created to represent the smoking data. An indicator variable of Europe versus all others
was created for geographic region. Demographic data and baseline characteristics were entered
into a multivariable Cox model for variable selection using bootstrap resampling (500 iterations
and a p-value criterion of 0.1 for retention). Those having a 50% or more probability of retention
were considered reliable and were entered into a second Cox model with the model selection
procedure of stepwise selection or backward elimination. The significance level to enter and
keep a variable was set at 0.05. These risk factors as well as the smoking indicator variables
met the proportional hazards assumption by plotting the log of the negative log of their
estimated survival distribution, log(−log(S(t))), versus time. The linearity assumption was
assessed and satisfied for all the continuous variables by plotting the logit of the events against
the continuous variable. The selected covariates from the two model selection methods were
compared to choose an optimal multivariable Cox model for each individual clinical endpoint.
Univariable interactions were tested in a Cox proportional hazards model, incorporating terms
for randomized treatment, smoking status, and the treatment-by-smoking status interaction, to
assess if treatment effect differed for current smokers versus never smokers and formers
smokers versus never smokers. Multivariable interactions were further analyzed by adding
covariates of baseline characteristics into the model.
Since this analysis is exploratory and meant to primarily be hypothesis generating, no
adjustments for multiple comparisons were made. All statistical analyses were performed with
SAS software (version 9.1.3; SAS Institute, Cary, North Carolina).
Results
Of the 12,152 patients included in this analysis, 2419 (19.9%) were current smokers, 6260
(51.5%) were former smokers, and 3473 (28.6%) never smoked. The median time of quitting
smoking for former smokers was 11 years (range, 0 to 69 years; mean 14.3 ±13.4 years). Table
1 shows the baseline characteristics of the study participants by smoking status. Compared
with never smokers, current smokers were younger, less frequently female and more likely to
be Caucasian. Current smokers were less likely to have a history of hypertension, diabetes,
heart failure, or prior revascularization, but were more likely to have peripheral arterial disease.
Mortality
All-cause mortality significantly differed according to smoking status: current smoker – 6.1%,
former smoker – 4.6%, never smoker – 4.3%, P=0.001 (Figure 1). After multivariable
adjustment, current smokers had an increased hazard of all-cause mortality (hazard ratio (HR)
2.58, 95% confidence interval (CI) 1.85 – 3.60, P<0.01) compared with never smokers; whereas
the hazard associated with former smokers compared with those who never smoked did not
reach statistical significance (HR 1.25, 95% CI 0.93 – 1.68, P=0.14) (Table 2). In multivariable
adjusted modeling, cardiovascular mortality (HR 2.26, 95% CI 1.48 – 3.45, P<0.01) and cancer
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mortality (HR 3.56, 95% CI 1.96 – 6.46, P<0.001) were elevated in current smokers compared
with never smokers. Former smokers compared with never smokers were at increased hazard
for cardiovascular mortality (HR 1.29, 95% CI 0.90 – 1.84, P=0.17) and cancer mortality (HR
2.08, 95% CI 1.24 – 3.49, P<0.01), although the former was not statistically significant.
Cardiovascular disease
The incidence of cardiovascular events (MI/stroke/cardiovascular death) was 8.4% in current
smokers, 7.1% in former smokers and 7.3% in never smokers (P=0.05). Compared with those
who never smoked, current smokers had an increased adjusted hazard of cardiovascular events
(HR 1.49, 95% CI 1.21 – 1.82, P<0.01). No excess hazard was seen for former smokers (HR
1.00, 95% CI 0.84 – 1.17, P=0.95). Current smokers had a greater hazard of stroke (HR 1.56,
95% CI 1.16 – 2.10, P<0.01); for MI, the excess risk did not reach statistical significance (HR
1.37, 95% CI 0.96 – 1.95, P=0.08). No significant difference was observed between former
smokers and never smokers for MI or stroke (Table 2).
Bleeding
Severe or moderate bleeding occurred in 3.1% of current smokers, 3.0% of former smokers
and 3.3% of never smokers (P=0.64). After multivariable adjustment, current smokers had a
higher hazard of severe or moderate bleeding (adjusted HR 1.48, 95% CI 1.09 – 2.00, P=0.01)
compared with never smokers. No statistically significant increased hazard for severe or
moderate bleeding was observed for former smokers (HR 1.06, 95% CI 0.83 – 1.34, P=0.64).
Current versus former smokers
After removing all patients who never smoked from the analysis, we performed multivariable
adjustments to compare current versus former smokers. Current smokers were at increased risk
for all-cause mortality (HR 1.72, 95% CI 1.39 – 2.12, P<0.01), cardiovascular mortality (HR
1.62, 95% CI 1.23 – 2.13, P<0.01), cancer mortality (HR 1.69, 95% CI 1.21 – 1.82, P<0.01),
cardiovascular events (HR 1.56, 95% CI 1.31 – 1.86, P<0.01), MI (HR 1.39, 95% CI 1.03 –
1.882, P=0.03), stroke (HR 1.56, 95% CI 1.18 – 2.05, P<0.01), and severe or moderate bleeding
(HR 1.38, 95% CI 1.05 – 1.83, P=0.02) compared with former smokers (Figure 2).
Clopidogrel
Finally, we assessed whether smoking status had any influence on the effect of clopidogrel. In
the overall cohort, all-cause mortality was 4.6% with clopidogrel and 5.0% with placebo (HR
0.91, 95% CI 0.78 – 1.07, P=0.27). A significant interaction existed between current smokers
and clopidogrel use for the outcome of all-cause mortality (P=0.018). Among current smokers,
clopidogrel was associated with a reduction in all-cause mortality (HR 0.68, 95% CI 0.49 –
0.94). No reduction in all-cause mortality was noted for either former smokers (HR 0.95, 95%
CI 0.75 – 1.19) or patients who never smoked (HR 1.14, 95% CI 0.83 – 1.58). Similarly, a
significant interaction existed between current smokers and clopidogrel for the outcome of
cardiovascular mortality (P for interaction =0.037) (Figure 3). As would be expected, no
significant interaction was noted for cancer mortality (P=NS).
The effect of clopidogrel on reducing cardiovascular events (MI/stroke/cardiovascular death)
did not differ according to smoking status (P for interaction=NS). Clopidogrel was associated
with a non-significant reduction in cardiovascular events in current smokers (HR 0.93, 95%
CI 0.71 – 1.22), former smokers (HR 0.83, 95% CI 0.69 – 1.00), and never smokers (HR 0.92,
95% CI 0.72 – 1.17). Although no significant interaction was noted, the benefit of clopidogrel
versus placebo on the risk of cardiovascular death or MI was greater in current smokers (HR
0.82, 95% CI 0.58 – 1.15) than in former smokers (HR 0.92, 95% CI 0.74 – 1.15) or those who
never smoked (HR 1.01, 95% CI 0.74 – 1.37).
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The relationship between clopidogrel versus placebo on severe or moderate bleeding is
illustrated in Figure 4. The risk of severe or moderate bleeding was increased in all smoking
categories. However, despite the lack of a significant interaction between smoking and bleeding
(P for interaction = NS), the magnitude of the risk of severe or moderate bleeding with
clopidogrel seemed to be related to smoking status. Specifically, clopidogrel was associated
with a statistically significant increase in the risk of bleeding in current smokers (HR 1.62,
95% CI 1.02 – 2.58, P=0.04). Among those who never smoked, however, the increase in risk
associated with clopidogrel was not statistically significant (hazard ratio, 1.31, 95% CI 0.90 –
1.90, P=0.15).
Discussion
Among patients with established cardiovascular disease, smoking status is a strong independent
risk factor for all cause mortality, cardiovascular mortality, cancer mortality, cardiovascular
events, and bleeding risk. Current smokers were at higher risk for each endpoint analyzed than
former smokers and those who never smoked. Interestingly, former smokers had similar
outcomes as those who had never smoked, except for higher cancer mortality. These data also
indicate that the benefit and risk of clopidogrel may be related to smoking status. Clopidogrel
was most effective in reducing all-cause and cardiovascular mortality, while simultaneously
causing an increase in the risk of bleeding in current smokers, a finding not observed in former
or never smokers.
We believe our data have clinical relevance for several reasons. Although smoking is known
to influence total and cause specific mortality in the general population16–18, data in patients
with cardiovascular disease is inconsistent27–31. In fact, several reports of patients following
a myocardial infarction or percutaneous revascularization described a lower adverse event rate
among smokers, described as the “smoker’s paradox”27–29. Nevertheless, despite the younger
age and considerably lower risk of current smokers at the time of enrollment in this study,
smoking has a widespread negative effect on health. The current analysis extends and reinforces
the increase in total and cause-specific mortality caused by smoking, as well as the increase in
bleeding in a population with established cardiovascular disease.
In our analysis, former smokers had a risk of all-cause mortality, cardiovascular mortality and
bleeding risk similar to those who never smoked. In contrast, the risk of cancer mortality
remained elevated in former smokers compared with those who never smoked. These data
suggest that the high risk of all-cause and cardiovascular mortality and severe or moderate
bleeding subsides after smoking cessation, while the risk of cancer mortality persists for a
longer period of time. Recent data from the Nurses Health Study is consistent, finding that
cardiovascular mortality decreases rapidly upon smoking cessation, whereas cancer related
mortality may take up to 20 years19.
The data suggest an important relationship between smoking status and the safety and efficacy
of clopidogrel therapy. A formal test of heterogeneity of the treatment effect of clopidogrel on
all-cause mortality and cardiovascular mortality was statistically significant, suggesting that
the benefit of clopidogrel may not be identical across smoking categories. The present finding
indicates that the effect of clopidogrel in reducing all-cause and cardiovascular mortality was
greatest among current smokers and that the benefit diminished significantly in former smokers
and never smokers. As expected, the effect of clopidogrel on cancer mortality was neutral and
was not modified by clopidogrel use. Surprisingly, the relationship between clopidogrel and
cardiovascular events was not significantly modified by smoking. Nevertheless, the apparent
benefit of clopidogrel in reducing fatal cardiovascular events in current smokers suggests a
real and plausible association. Overall, this data in accordance with others32, supporting recent
ex vivo data which showed greater platelet inhibition by clopidogrel in current smokers
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compared with never smokers20. These data, combined with this clinical analysis, suggests
that factors such as smoking modify the benefit of clopidogrel. Cigarette smoking induces
CYP1A2 activity21, a hepatic enzyme involved in the metabolism of clopidogrel. Thus, the
greater platelet inhibition demonstrated by Bliden and colleagues20 and the clinical differences
observed in the current study may be explained via the induction of CYP1A2. An alternative
explanation for the association between smoking and clopidogrel may be partly explained by
the lower release of tissue plasminogen activator in current smokers8. Current smokers with
impaired endogenous fibrinolysis may benefit most from antiplatelet therapy, an observation
noted in thrombolytic therapy and coined the “smoker’s paradox”33. Since clopidogrel is
known to increase bleeding, we evaluated whether smoking would modulate the excess
bleeding risk with clopidogrel. Although no significant interaction was detected for bleeding
risk and smoking, current smokers had the greatest risk of bleeding from clopidogrel. This
excess risk was attenuated in a stepwise fashion in former and current smokers.
Limitations
There are several important limitations of this analysis. First, it should be reemphasized that
this post hoc subgroup analysis ought to be considered hypothesis-generating. Our analyses of
smoking status are based on a single base-line determination that may have changed over the
study period; we do not have data on smoking following enrollment. However,
misclassifications of smoking status would probably have attenuated the true association
between current smokers and adverse events; thus, these results may represent an underestimate
of the risk associated with current smoking.
Conclusions
Among patients with established cardiovascular disease, current smokers are at increased
hazard for all-cause, cardiovascular and cancer specific mortality, cardiovascular events, and
severe or moderate bleeding. These data also suggest that the benefit and risk of clopidogrel
may be modified by smoking status, thus providing additional evidence to support the
hypothesis that the antiplatelet effect of clopidogrel may be enhanced in current smokers.
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Figure 1. Kaplan-Meier curves of cardiovascular events stratified by smoking status
Cumulative incidence of all-cause mortality, cardiovascular mortality, and cancer mortality
stratified by smoking status.
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Figure 2. Adjusted hazard ratio for the cardiovascular endpoints in current smokers versus former
smokers
Hazard ratio and 95% confidence interval adjusting for the cardiovascular risk factors for the
efficacy and safety endpoints for current smokers versus former smokers in the ever smoking
patients (n=8,679) with established cardiovascular disease.
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Figure 3. Subgroup analysis of clopidogrel versus placebo on a) all-cause mortality, b)
cardiovascular mortality, and c) cancer mortality by smoking status
Frequencies, cumulative event rates, hazard ratios, 95% confidence intervals, and p-values for
the multivariable interaction between the treatment effect and the smoking subgroup variables
(presented as indicator variables for current smoking and former smoking, respectively) are
shown for the risk of adverse events associated with clopidogrel by smoking status among the
12,152 patients with established cardiovascular disease enrolled in CHARISMA. CS, current
smoking. FS, former smoking.
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Figure 4. Hazard ratio of severe or moderate bleeding in randomized assignment to clopidogrel
versus placebo therapy according to smoking status
The increase in the risk of severe or moderate bleeding associated with the use of clopidogrel
was 62 percent in current smokers (3.9% vs 2.4%, P=0.04), 43 percent in former smokers (3.5%
vs 2.5%, P=0.02), and 31 percent in never smokers (3.7% vs 2.8%, P=0.15) (P for interaction
>0.05).
Berger et al. Page 13
Circulation. Author manuscript; available in PMC 2010 December 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Berger et al. Page 14
Table 1
Baseline demographics by smoking status
Current Smokers (n=2419) Former Smokers (n=6260) Non- Smokers (n=3473) P- value
Demographics
Age (yr, mean ± SD) 60.4 ± 8.5 64.3 ± 9.4 66.1 ± 9.8 <.001
Female sex (%) 24.6 17.7 46.1 <.001
Race or Ethnic group (%)
 Caucasian 92.1 92.5 88.7 <.001
 Black 3.1 2.5 2.9 0.202
 Asian/Oriental 3.7 3.9 7.3 <.001
European region (%) 48.4 39.0 42.9 <.001
BMI (mean ± SD) 27.0 ± 5.0 28.5 ± 4.8 28.2 ± 4.9 <.001
Clinical History (%)
Hypertension 62.8 69.5 74.8 <.001
Hypercholesterolemia 68.5 74.7 67.8 <.001
Heart failure 5.5 6.7 5.8 0.037
Prior MI 34.4 47.3 35.3 <.001
Prior stroke 30.5 24.4 38.8 <.001
Prior TIA 13.2 12.0 17.2 <.001
Diabetes 24.9 31.6 34.3 <.001
Diabetic nephropathy 3.4 4.6 4.6 0.034
PAD 42.3 27.8 12.6 <.001
Prior PCI 20.3 31.1 23.5 <.001
Prior CABG 12.3 26.6 22.2 <.001
Medication (%)
Aspirin 94.2 96.6 94.4 <.001
Beta blockers 39.6 53.4 49.3 <.001
ARBs 10.6 14.3 16.3 <.001
ACE-inhibitors 53.7 62.8 62.9 <.001
Statins 60.3 70.9 61.5 <.001
Other lipid lowering
therapies
6.4 7.4 6.7 0.182
Diabetic medications 21.4 27.7 30.5 <.001
Insulin 7.2 9.4 11.0 <.001
Other oral
hypoglycemic agents
16.3 21.6 23.3 <.001
Circulation. Author manuscript; available in PMC 2010 December 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Berger et al. Page 15
Table 2
Hazard Ratios for death and cardiovascular events according to smoking status
Unadjusted* hazard ratio (95 percent
confidence interval)
Fully adjusted^ hazard ratio (95
percent confidence interval)
All-cause mortality
 Non-smoker 1.00 1.00
 Former smoker 1.17 (0.88 – 1.56) 1.25 (0.93 – 1.68)
 Current smoker 1.86 (1.36 – 2.56) 2.58 (1.85 – 3.60)
Cardiovascular mortality
 Non-smoker 1.00 1.00
 Former smoker 1.16 (0.81 – 1.65) 1.29 (0.90 – 1.84)
 Current smoker 1.62 (1.08 – 2.42) 2.26 (1.48 – 3.45)
Cancer mortality
 Non-smoker 1.00 1.00
 Former smoker 1.79 (1.07 – 3.00) 2.08 (1.24 – 3.49)
 Current smoker 2.26 (1.27 – 4.04) 3.56 (1.96 – 6.46)
Cardiovascular mortality, myocardial infarction or stroke
 Non-smoker 1.00 1.00
 Former smoker 0.95 (0.82 – 1.11) 1.00 (0.84 – 1.17)
 Current smoker 1.17 (0.97 – 1.41) 1.48 (1.21 – 1.82)
Cardiovascular mortality or myocardial infarction
 Non-smoker 1.00 1.00
 Former smoker 1.05 (0.87 – 1.27) 1.00 (0.81 – 1.22)
 Current smoker 1.21 (0.96 – 1.52) 1.46 (1.14 – 1.88)
Myocardial infarction
 Non-smoker 1.00 1.00
 Former smoker 1.13 (0.87 – 1.48) 0.99 (0.75 – 1.31)
 Current smoker 1.19 (0.86 – 1.65) 1.37 (0.96 – 1.95)
Stroke
 Non-smoker 1.00 1.00
 Former smoker 0.78 (0.62 – 0.99) 1.09 (0.86 – 1.38)
 Current smoker 0.99 (0.74 – 1.31) 1.56 (1.16 – 2.10)
Severe or moderate bleeding
 Non-smoker 1.00 1.00
 Former smoker 0.90 (0.71 – 1.14) 1.06 (0.83 – 1.34)
 Current smoker 0.97 (0.73 – 1.30) 1.48 (1.09 – 2.00)
*
Treatment allocation (clopidogrel versus placebo) was forced into the model. All-cause mortality and cardiovascular mortality were also adjusted
for the interaction term between treatment allocation and smoking status.
^
Adjusted for model-selected covariates from the pool of age, sex, ethnicity, geographic region (Europe versus all others), body weight, history of
heart failure, hypercholesterolemia, hypertension, diabetes mellitus, diabetic nephropathy, transient ischemic attack, history of myocardial infarction,
stroke, peripheral arterial disease, percutaneous coronary intervention, coronary artery bypass graft, and baseline medications (aspirin, beta blocker,
ACE-inhibitor, ARB, oral hypoglycemic). Treatment allocation (clopidogrel versus placebo) was forced into the model. All-cause mortality and
cardiovascular mortality were also adjusted for the interaction term between treatment allocation and smoking status.
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